BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

Corporate Breaking News

Home : BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

Apr 02 2019	BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance
BERGEN, Norway, April 2, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces preclinical data strengthening bemcentinib's broad potential in reversing...


Source:https://www.prnewswire.com:443/news-releases/bergenbio-preclinical-data-presented-at-aacr-reinforces-bemcentinibs-potential-to-reverse-tumour-immunosuppression-and-therapy-resistance-300822529.html

Related News
» Cash Homes MN Releases The February 2019 Carver, Dakota and Scott County Edition of the Stop Foreclosure MN Report » Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11